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Objective: To continue evaluation of the use of acyclovir suppression in late pregnancy after first episode genital
herpes simplex virus (HSV) infection, using an open-label study design.
Methods: Ninety-six women diagnosed with genital herpes for the first time in the index pregnancy were pre-
scribedsuppressiveacyclovir 400 mg orally three times daily from 36 weeks untildelivery in an open-label fashion.
Herpes cultures were obtained when patients presentedfor delivery. Vaginal delivery was permitted if no clinical
recurrencewaspresent;otherwise aCesareandeliverywasperformed.NeonatalHSVcultureswereobtainedand
infants were followed clinically. Rates of clinical and asymptomatic genital herpes recurrences and Cesarean
delivery for genital herpes were measured, and 95% confidence intervals were calculated.
Results: In82patients(85%)compliantwiththerapy,only1%hadclinicalHSVrecurrencesatdelivery.Inanintent
to treat analysis of the entire cohort, 4% had clinical recurrences(compared with 18–37% in historical controls).
Asymptomatic sheddingoccurredin1%ofwomen withoutlesionsatdelivery.Two of the fourclinicalrecurrences
were HSV-culture positive. No significant maternal or fetal side-effects were observed.
Conclusions: In clinical practice the majority of patients are compliant with acyclovir suppression at term. The
therapy appears tobeeffective at reducingclinical recurrencesaftera first episodeof genitalherpes complicating a
pregnancy.
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As many as 5% of women have a history of genital
herpes and are at risk for transmitting herpes
simplex virus (HSV) to their infants during
delivery, should they have a peripartum recurr-
ence1. Many of these women will experience their
first episode of genital herpes while they are preg-
nant,and they have a high risk of recurrenceat the
time of delivery2,3. To avoid intrapartum HSV
exposureandneonatalinfection,itiscurrentlyrec-
ommended that pregnant women with visible
genital herpes lesions or prodromal symptoms at
the time of labor undergo Cesarean delivery.
Gravidas without visible lesions or prodromal
symptoms should be allowed to continue in labor,
because they have a low risk of neonatal HSV
transmission4. Using these guidelines, it is esti-
mated that one poor neonatal outcomefrom HSV
infection is averted (at a cost of 2.5 million dollars)
for every 1580 Cesarean deliveries performed for
maternal clinical HSV recurrences5.
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Clinical study 75We previously reported a randomized, con-
trolled trial that compared acyclovir suppression
withplacebointhelastseveral weeksofpregnancy.
We asked whether acyclovir treatment could
decrease the incidence of clinical herpes recur-
rences and thereby decrease the need for cesarean
section for this indication2. In compliant patients
none of the acyclovir-treated ones had a recur-
rence at the time of delivery, compared with 36%
of theplacebo-treatedpatients. In an intentto treat
analysis, 8% of the acyclovir-treated patients, and
34% of the placebo-treated patients, had a recur-
rence at delivery. The differences between treat-
ment groups in both analyses were statistically
significant, although the number of patients en-
rolled in the initial study was relatively small
(n = 46). The purpose of the present study was to
extendourinvestigationoftheeffectofsuppressive
acyclovir on recurrent genital herpes after a first
episode infection in pregnancy, using an open-
label study design.
PATIENTS AND METHODS
Eligible patients included any gravida whose first
clinical episode of genital herpes occurred during
the index pregnancy. All denied a prior diagnosis
of herpes, or having had similar lesions before
becoming pregnant. The diagnosis was confirmed
by a positive viral culture for herpes simplex virus,
but viral typing was not performed. Women with
primary infection, women with first genital, non-
primary episodes, and women with a first clinical
episodeofrecurrentdiseasewerealleligible6.Sero-
logy was not performed to distinguish between
these groups of patients. Exclusion criteria for
enrollment included a serum creatinine level
greater than 1.5 mg/dl, immunosuppressive
diseases (e.g., human immunodeficiency virus
infection), a known requirement for Cesarean
delivery (e.g., previous Cesarean with a classical
uterineincision), enrollment in anotherstudy pro-
tocol, a gestational age of greater than 36 weeks
uponidentification,delivery before36weeks’ ges-
tation or previous acyclovir intolerance. Subjects
were excluded from evaluation of efficacy for
voluntary withdrawal, noncompliance with the
study protocol, loss of follow-up for delivery, or
delivery within one week of beginning treatment.
A patient was considered to be noncompliant if
she had not taken any study medication for 7
or more days prior to delivery. An intent to treat
analysis was performed,whichincludedallpatients
with known outcomes. Informed consent was
obtained from eligible patients by 36 completed
weeks of gestation. At 36 weeks’ estimated gesta-
tional age, patients were prescribed acyclovir
400 mg orally,threetimes daily untildelivery. The
women were evaluated weekly after 36 weeks’
gestation and were questioned at each visit about
genital lesions, prodromal symptoms, compliance,
and side-effects from the treatment. An examina-
tion for genital HSV lesions was performed at each
visit. HSV cultures were obtained only if the
patient described prodromal symptoms or if a
lesion was identified. The collection, handling,
and culture techniques have been described
previously2,7.
Upon presentation for delivery the patients
were examined for genital lesions and questioned
regardingprodromalsymptoms.Herpesculturesof
the usual lesion site and cervix were obtained to
detect asymptomatic viral shedding. Asympto-
matic shedding was defined as a positive maternal
HSV culture in the absence of prodromal symp-
toms orvisible lesions. Anyvisible genital orcervi-
callesionswerealso culturedforHSVandclassified
as clinical recurrences. Obstetric housestaff or
nurse practitioners who had been instructed in
properviral culturecollection techniquesobtained
the samples from patients upon admission to the
laboranddelivery unit.Theacyclovirwasnotcon-
tinued intrapartum. Patients underwent Cesarean
delivery if prodromal symptoms or lesions suspi-
cious for genital herpes were present, regardless of
the length of time the amniotic membranes had
been ruptured. They were allowed to labor if
prodromal symptoms and lesions were absent.
The pediatricians were informed of the
mother’s participation in the study and a physical
exam was performed upon the infant’s admission
to the newborn nursery. Neonatal HSV cultures
were taken fromtheconjunctiva,oropharynx,and
rectum 24–72 hours after delivery. The infants
were observed for clinical evidence of acyclovir
toxicity (abnormal renal, liver or central nervous
system function) and HSV infection. Prophylactic
acyclovir therapy was not administered unless the
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ment was left to the discretion of the attending
pediatrician. Mothers were instructed to contact
the investigators for any problems in the first
month after discharge and the infants’ medical
records were reviewed at least 1 month after
delivery.
Apart from the fact that patients were treated in
an open-label fashion, this study protocol was the
same as the one used in our earlier randomized
clinical trial2. The primary outcomemeasured was
thefrequencyof clinical genital herpes recurrences
at delivery. Secondary outcomes were the rate of
asymptomatic and total HSV detection by culture
and the frequency of cesarean delivery for genital
herpes. Rates and exact 95% confidence intervals
were calculated. The Food and Drug Administra-
tion granted an Investigational Drug Number for
thisprotocol,andtheinvestigationalreview boards
of the University of Texas Southwestern Medical
Center, Parkland Health and Hospital System and
St Paul Medical Center granted approval for the
study.
RESULTS
Ninety-nine patients with a diagnosis of first epi-
sodegenital herpes duringpregnancywere eligible
and agreed to participate in the open-label trial.
Seventeen womenbegan butdid notcompletethe
study protocol,of whom 3 were lost to follow-up.
These 14 women were excluded from the evalua-
tion of theefficacy of the therapeutic regimen, but
all 96 patients with a known outcome were
included in the intent to treat analysis8,9.
Themean gestational age at diagnosis ofthefirst
herpes outbreak was 21.1 weeks. The mean total
number of herpes outbreaks (including the initial
outbreak) during the pregnancies was 1.3. Other
maternal characteristics are provided in Table 1.
Eighty-two patientscompletedthestudyprotocol.
One (1.2%) patient had clinically-evident genital
herpes recurrence at delivery and required a
Cesarean forHSV. Her HSV culturewas negative.
Asymptomatic shedding was documented in 1/70
(1.4%) patientswhohad aherpescultureat presen-
tation for delivery (Table 2). The 14 women with
known outcomes who were not evaluable were
analyzed. Six women delivered within 1 week of
starting prophylaxis, five withdrew from the study
and three women were noncompliant. Three of
these women (21%) had clinical recurrences at
delivery, and two of the three (67%) were
HSV-culture positive. Eight of the other 11
women had HSV cultures performed at delivery,
and all were negative.
The 82 women who completed the trial were
combined with the 14 women who were not
evaluable for efficacy. In this intent to treat analy-
sis, four of 96 (4.2%) of the women had a clinical
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Characteristic Patients (n = 99)
Ethnicity
Black
White
Hispanic
Age
Parity
Gestational age at diagnosis
Outbreaks during pregnancy*
Gestational age at delivery*
Birthweight*
5-minute Apgar score*
Cord pH*
63%
7%
30%
21.9 years
1
21.1 weeks
1.3
39.1 weeks
3279 g
9
7.17
*n used in calculations may be different owing to unavailability of
information for some patients
Table 1 Maternal and neonatal characteristics; data
presented as percentage, mean, or median of the sample
Recurrences at
delivery
Exact 95%
confidence
interval
Efficacy analysis
Symptomatic recurrences
Asymptomatic shedding
Total HSV detection
(symptomatic +
asymptomatic)
Intent to treat analysis
Symptomatic recurrences
Asymptomatic shedding
Total HSV detection
(symptomatic +
asymptomatic)
1/82 (1.2%)
1/70 (1.4%)
1/71 (1.4%)
4/96 (4.2%)
1/78 (1.3%)
3/82 (3.7%)
0.03–6.61
0.04–7.70
0.04–7.60
1.15–10.33
0.03–6.94
0.76–10.32
HSV, herpes simplex virus
Table 2 Genital herpes recurrences at deliveryrecurrence of genital herpes at labor and under-
went Cesarean delivery. Two of the four women
(50%) with clinical recurrences at delivery had
positive genitalHSV cultures.AsymptomaticHSV
shedding occurred in 1.3% (1/78) (Table 2).
The mean gestational age at delivery was 39.1
weeks and the mean birthweight was 3279 g. All
but one infant had 5-minute Apgar scores greater
than 7. One infant received prophylactic antiviral
therapy for 3 days. This neonate was from a
noncompliant mother who had prolonged rup-
tured membranes in the presence of a genital
herpes lesion and underwent Cesarean delivery.
The infant’s HSV cultures were negative, and he
ultimately didwell.Althoughnoinfanthadclinical
evidence of neonatal herpes, one did have a posi-
tive HSV culture when tested at less than 24 hours
after delivery, a breach of the study protocol.
The mother was clinically asymptomatic, and the
maternalHSV culturesobtainedat presentationfor
delivery were negative. The infant was observed
without treatment. Repeat herpes cultures ob-
tained at the appropriate time, between 24 and
72 hours of life, were negative. No infant experi-
enced any clinically apparent neurological,
hepatic, or renal complications or other adverse
effects attributableto acyclovir duringtheneonatal
period.
DISCUSSION
Historically, women with a first episode genital
herpes outbreak in pregnancy have a high rate of
recurrence (18–37%) at delivery2,3,10. In an effort
to prevent intrapartum herpes virus transmission,
obstetricians generally resort to Cesarean delivery
when patients present for delivery with recurrent
genital HSV lesions or prodromal symptoms.
Under current guidelines a vaginal delivery is
appropriate in the absence of these findings1,4.
Daily acyclovir therapy suppresses recurrent geni-
tal HSV outbreaksin the nonpregnantadult11, and
this treatment has been shown to help prevent
herpes reactivation at delivery2,11,12. Our study
provides further evidence that acyclovir suppres-
sive therapy in the last several weeks of pregnancy
decreases genital herpes recurrences at the time of
delivery in women whose first genital herpes epi-
sode occurred during that pregnancy. However,
acyclovir suppression does not completely
eliminate the possibility of clinical reactivations,
asymptomatic shedding, or even neonatal expo-
sure to HSV.
A theoretical concern has been whether
symptomatic recurrences would be converted to
asymptomatic shedding episodes by suppressive
treatment, thus potentially increasing an infant’s
perinatal exposure to HSV through a vaginal
delivery. Acyclovir suppression in nonpregnant
patients decreases asymptomatic shedding by up to
96%13, however this association has not been eval-
uated in pregnantwomen.Thereported incidence
of asymptomatic HSV shedding at any given time
in pregnant women with genital herpes is about
1–2%14–16. In the present study suppressive acyclo-
vir therapy decreased the frequency of recurrent
HSV lesions withoutapparentlyincreasing thefre-
quency of asymptomatic viral shedding. These
results are reassuring, although they do not
demonstratethe same decrease in viral excretion as
reported for nonpregnant patients.
On short-term follow-up there were no clini-
cally apparent adverse effects on any of the neo-
nateswhohadprenatalexposuretoacyclovir,1200
mg daily, at term. Our previous study2, and
those of Stray-Pedersen12 and Brocklehurst and
colleagues10donotindicatethatanyharm iscaused
by maternal acyclovir suppression. Data from the
Acyclovir in Pregnancy Registry do not suggest
adverse outcomes attributable to acyclovir in
over 1000 prenatal exposures at various gestational
ages17. Additional anecdotal evidence of acyclovir
safety is provided indirectly through reported
pediatric clinical experience. Both term and
preterm infants treated daily with intravenous
acyclovir tolerate the drug well18,19. Furthermore,
the fetal serum levels in gravidas taking 1200 mg
acyclovir daily have been reported to be much
lower than the acyclovir levels achieved during
neonatal parenteral treatment18–20. The lack of
adverse effects is reassuring. However, in the
absence of large, controlled trials specifically
designed to assess neonatal outcomes, including
hematologic, renal and hepatic parameters, it
cannot yet be concluded that prenatal suppressive
acyclovir therapy is completely safe for the fetus.
Further evaluation of short- and long-term neo-
natal outcomes is necessary.
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an open-label trial, rather than a double blind,
prospective, randomized study. Although the
study design is not as rigorous, we felt that it was
not ethical to continue the randomization to
placebo once the earlier study demonstrated a
significant benefit. Other limitations include not
identifying HSV type and lack of discrimination
between primary, first-episode nonprimary, and
first clinically apparent recurrent disease. How-
ever, at this time, reliable herpes simplex
type-specific serology was not available outside
reference laboratories. Our study design reflected
the level of information most clinicians would
have, that is clinical history and herpes culture
results.
When the findings in this cohort are combined
withthosefromourpreviousrandomized trial, the
clinical experience with prophylaxis in this group
of women with genital herpes is enhanced. Using
theevaluable patientsinbothgroups,1/103(1.03%;
95% CI, 0.02–5.3) had clinical recurrences. Using
all the treated patients in both groups, 6/122
(4.9%; 95% CI, 1.83–10.4) had clinical recur-
rences. These combined frequencies are
dramatically and consistently low given the high
rate of expected recurrences of 34–36% from our
placebo-treated cohort in the previous study2.
Furthermore, the observed rate of recurrences in
patientswhostoppedtaking suppressive therapy in
this study (3 of 14 or 21%) and in the combined
cohort (5 of 19 or 26%) underscores the high
activity of disease in this group. It also emphasizes
the increased risks of recurrence associated with
noncompliance.
CONCLUSIONS
This study demonstrates that acyclovir suppressive
therapygiven from36weeks’gestationuntildeliv-
ery prevents recurrent genital HSV at the time of
delivery and is associated with a low frequency of
cesarean section for recurrent genital herpes in
women who experienced their first episode of
genital herpes earlier during the pregnancy. This
benefit confirmsand extendsour previous findings
outside a randomized trial. Although the small
sample size does not provide sufficient power to
drawconclusionsregardingtheimpactofacyclovir
suppression ofasymptomatic viral sheddingorfetal
outcome, no changes were detected in the rate of
asymptomatic HSV shedding at delivery nor were
any short-term, adverse neonatal effects detected.
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